.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,323,630

« Back to Dashboard

Claims for Patent: 8,323,630

Title:Self-preserved aqueous pharmaceutical compositions
Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred. Limiting the amount of divalent metals other than zinc and the amount of ionized salts present has also been determined to be important to maximize the antimicrobial activity of the balanced buffer systems.
Inventor(s): Kabra; Bhagwati P. (Euless, TX), Chowhan; Masood A. (Arlington, TX), Schneider; L. Wayne (Crowley, TX), Han; Wesley Wehsin (Arlington, TX)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:13/086,950
Patent Claims: 1. A multi-dose, self-preserved ophthalmic solution, comprising: a therapeutically effective amount of an ophthalmically acceptable therapeutic agent; zinc ions at a concentration of 0.1 to 0.4 mM; borate at a concentration of 0.5 to 1.2% w/v; propylene glycol at a concentration of 0.25 to 1.25%; and sorbitol at a concentration of 0.05 to 0.5% w/v; wherein: (i) the concentration of anionic species in the solution is less than 15 mM; (ii) the concentration of multivalent buffering anions in the solution is less than 5 mM; (iii) the concentration of multivalent metal cations other than zinc in the solution is less than 5 mM; and (iv) the solution exhibits sufficient antimicrobial activity to allow the solution to satisfy USP 27 preservative efficacy requirements.

2. A solution according to claim 1, wherein the zinc ions are provided in the form of zinc chloride in the solution at a concentration of 0.001 to 0.005% w/v.

3. A solution according to claim 1, wherein the borate consists of boric acid.

4. A solution according to claim 1, wherein the solution has a pH from 5.5 to 5.9.

5. A solution according to claim 1, further comprising a non-ionic surfactant.

6. A solution according to any one of claim 1, 3, 4 or 5, wherein the therapeutic agent is a prostaglandin analog.

7. A solution according to any one of claim 1, 3, 4 or 5 wherein the therapeutic agent is travoprost.

8. A multi-dose, self-preserved ophthalmic solution, comprising: (a) a therapeutically effective amount of travoprost; (b) a non-ionic surfactant; (c) zinc chloride at a concentration of 0.001 to 0.005% w/v; (d) boric acid at a concentration of 0.5 to 1.2% w/v; (e) propylene glycol at a concentration of 0.25 to 1.25% w/v; and (f) sorbitol at a concentration of 0.05 to 0.5% w/v; wherein: (i) the solution has a pH from 5.5 to 5.9; (ii) the concentration of anionic species in the solution is less than 10 mM; (iii) the concentration of multivalent buffering anions in the solution is less than 5 mM; and (iv) the concentration of multivalent metal cations other than zinc in the solution is less than 5 mM; and (v) the solution exhibits sufficient antimicrobial activity to satisfy USP 27 preservative efficacy requirements based solely on the anti-microbial properties of one or more of components (a)-(f) together with the pH of the solution.

9. A solution according to claim 8 wherein the solution does not contain multivalent buffering anions and does not contain multivalent cations other than zinc.

10. A multi-dose ophthalmic solution, consisting essentially of: (a) travoprost at a concentration of 0.004% w/v; (b) zinc chloride at a concentration of 0.0025% w/v; (c) polyoxyl 40 hydrogenated castor oil at a concentration of 0.5% w/v; (d) boric acid at a concentration of 1.0% w/v; (e) propylene glycol at a concentration of 0.75% w/v; (f) sorbitol at a concentration of 0.25% w/v; (g) sodium hydroxide and/or hydrochloric acid in an amount sufficient to cause the solution to have a pH from 5.5 to 5.9; and (h) water; wherein: (i) the concentration of anionic species in the solution is less than 10 mM; (ii) the solution does not contain multivalent buffering anions; and (iii) the solution does not contain multivalent cations other than zinc.

11. A solution according to claim 10 wherein the solution exhibits sufficient antimicrobial activity to satisfy USP 27 preservative efficacy requirements based solely on the anti-microbial properties of one or more of components (a)-(f) together with the pH of the solution.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc